Multidisciplinary care is an important aspect of the management of patients with multiple myeloma, providing care to manage disease-, treatment-, and patient-related complications. In addition to the involvement of hematology/oncology professionals, the broad reaching effects of multiple myeloma may require other specialty input.1 With a relatively high prevalence of renal disease in patients with multiple myeloma, active consideration of nephrology involvement should take place to address challenges with renal function.1 Orthopedic and dental specialists may be required to assist to address complications associated with MM-associated bone disease, and cardiologists may be called upon to address potential cardiac toxicity.1 Pharmacists, nurse practitioners, and nurses also provide key supportive roles for patients with multiple myeloma.
Another key advantage of multidisciplinary care is the capacity to manage potential side effects of key therapies such as CAR T-cell therapies and bispecific antibodies, many of which target B-cell maturation antigen.2 Potential toxicities associated with these therapies include cytokine release syndrome, neurotoxicity, infection, and cytopenias. Management of these adverse events may require multidisciplinary collaboration with other specialties, including neurology, infectious diseases, and critical care.2
